Signal peptide-CUB-EGF-like domain-containing protein 3 (SCUBE3) is a secreted glycoprotein that is overexpressed in lung cancer tumor tissues and is correlated with the invasive ability in a lung cancer cell line model. These observations suggest that SCUBE3 may have a role in lung cancer progression. By exogenous SCUBE3 treatment or knockdown of SCUBE3 expression, we found that SCUBE3 could promote lung cancer cell mobility and invasiveness. Knockdown of SCUBE3 expression also suppressed tumorigenesis and cancer metastasis in vivo. The secreted SCUBE3 proteins were cleaved by gelatinases (matrix metalloprotease-2 (MMP-2) and MMP-9) in media to release two major fragments: the N-terminal epidermal growth factor-like repeats and the C-terminal complement proteins C1r/C1s, Uegf and Bmp1 (CUB) domain. Both the purified SCUBE3 protein and the C-terminal CUB domain fragment, bound to transforming growth factor-b (TGF-b) type II receptor through the C-terminal CUB domain, activated TGF-b signaling and triggered the epithelial-mesenchymal transition (EMT). This process includes the induction of Smad2/3 phosphorylation, the increase of Smad2/3 transcriptional activity and the upregulation of the expression of target genes involved in EMT and cancer progression (such as TGF-b1, MMP-2, MMP-9, plasminogen activator inhibitor type-1, vascular endothelial growth factor, Snail and Slug), thus promoting cancer cell mobility and invasion. In conclusion, in lung cancer cells, SCUBE3 could serve as an endogenous autocrine and paracrine ligand of TGF-b type II receptor, which could regulate TGF-b receptor signaling and modulate EMT and cancer progression.
Introduction
Metastasis, the major cause of most cancer-related deaths, is a sophisticated process that consists of three distinct steps: invasion, survival and arrest in the bloodstream, and metastatic colonization (Steeg, 2006) . The first step, invasion, consists of the loss of tumor cell-cell adhesion, gain of cancer cell mobility, deposition of the extracellular matrix and invasion into adjacent tissues. The epithelial-mesenchymal transition (EMT) is often associated with these behaviors and is regarded as an important mechanism for invasion (Huber et al., 2005) . Extracellular matrix and many secreted soluble factors are known to be involved in EMT through several signaling pathways, such as the Wnt (Yook et al., 2005 (Yook et al., , 2006 , transforming growth factor-b (TGF-b) (Valcourt et al., 2005) , Hedgehog (Karhadkar et al., 2004; Feldmann et al., 2007) , Notch (Timmerman et al., 2004; Leong et al., 2007) and nuclear factor kB (Huber et al., 2004) pathways. The secretion of these autocrine or paracrine factors by cancer cells or stromal cells into the tumor microenvironment is pivotal in the process of metastasis and the malignant progression of cancer. The identification of the tumor promoting factors found in the microenvironment and the elucidation of their mechanism of action will provide insight into carcinogenesis and potentially provide new therapeutic targets for cancer patients.
Signal peptide-CUB-EGF-like domain-containing protein 3 (SCUBE3) is a secreted cell-surface glycoprotein that was first identified in human umbilical vein endothelial cells (Wu et al., 2004) . SCUBE3 consists of five motifs: an N-terminal signal peptide, followed by nine copies of EGF (epidermal growth factor)-like repeats, a spacer region, three cysteine-rich domains and a complement proteins C1r/C1s, Uegf and Bmp1 (CUB) domain at the C-terminus. SCUBE3 can be cleaved to release the N-terminal EGF-like repeats and the C-terminal CUB domain, which are implicated in protein-protein interactions (Bork and Beckmann, 1993; Rao et al., 1995; Yang et al., 2007) . SCUBE3 has recently been discovered to be involved in murine cardiac hypertrophy, through TGF-b1-mediated transcriptional activation (Yang et al., 2007) . SCUBE3 has also been implicated in murine embryogenesis and development, as scube3 transcripts are expressed prominently in developing tissues (Haworth et al., 2007) . Our laboratory has recently discovered that SCUBE3 is also highly expressed in extremely invasive lung cancers, and we are interested in further investigating the role it may have in metastasis.
In this study, we found that SCUBE3 expressed and secreted by cancer cells could be further cleaved by matrix metalloprotease-2 (MMP-2) and MMP-9 to release two major fragments: the N-terminal EGF-like repeats and the C-terminal CUB domain. The fulllength SCUBE3 and its CUB domain fragment can bind the TGF-b type II receptor (TbR-II) of cancer cells, activate TGF-b signaling, promote EMT and increase cancer cell mobility. Our results support the notion that SCUBE3 may act as an autocrine and paracrine regulator in lung cancer cells and have an important role in triggering EMT and promoting cancer progression.
Results

SCUBE3 is highly expressed in lung cancer tissues and is correlated with cancer cell invasive ability
The SCUBE3 expression profile in normal and cancer tissues was analyzed by in silico data mining, using the expressed sequence tag (EST) clustering from the ECgene database (http://genome.ewha.ac.kr/ECgene/). This analysis showed that the SCUBE3 mRNA was highly expressed in lung cancer tissues ( Figure 1a ). Primary cancer specimens from 18 patients with histologically confirmed non-small cell lung cancer were studied. SCUBE3 expression in tumors was at least twofold higher than in the adjacent normal tissues in 10 (56%) out of 18 paired specimens in reverse transcriptase PCR analysis (Figure 1b ). SCUBE3 protein expression was also examined immunohistochemically in tumor specimens from another 60 non-small cell lung cancer patients. The clinical and pathologic features of the patients analyzed by immunohistochemistry are summarized in Supplementary Table S1 . Representative images of SCUBE3-positive lung adenocarcinoma and SCUBE3-negative adjacent normal bronchiole identified by immunohistochemical staining are shown in Figure 1c . SCUBE3 is predominantly expressed in the epithelial cells in lung cancer tissues. In the adjacent normal lung tissues, the SCUBE3 expression is mainly in the bronchial epithelial cells. Other lung parenchymal cell types, such as smooth muscle fibers, may also Figure 1 SCUBE3 is highly expressed in lung cancer tissues and is correlated with cancer cell invasive ability. (a) The EST expression analysis of the SCUBE3 gene in different normal and cancerous tissues was modified from the ECgene database (http://genome. ewha.ac.kr/ECgene/). (b) The SCUBE3 expression in tumor and adjacent normal tissue of non-small cell lung cancer patients was assessed by reverse transcriptase PCR. Gb-like gene was used as the internal control. Normal tissues (N); tumor (T). SCUBE3 level was normalized to the internal control and the ratio of SCUBE3 expression in tumors compared with the paired normal tissues (T/N) is shown. (c) Immunohistochemical staining of SCUBE3 expression in paired normal and tumor specimens from a non-small cell lung cancer patient. (d) The mRNA and protein expression levels of SCUBE3 in a panel of human lung adenocarcinoma cell lines, CL 1-0 , CL 1-1 and CL 1-5 , in ascending order of invasiveness were detected by reverse transcriptase PCR and immunoblotting with an anti-SCUBE3 antibody, respectively. Gb-like gene and bactin were used as the internal controls. The asterisk indicates a nonspecific band. The invasive ability of these lung cancer cell lines was detected by the in vitro invasion assay. Experiments were performed as three independent experiments in triplicate. Values are reported as the mean ± s.d. Figure S1 ). In addition, histological examination indicated that SCUBE3 was highly expressed in lung cancers, but was expressed at a low level in the adjacent normal tissues in 34 (57%) out of 60 specimens. The statistical analysis of the correlation between SCUBE3 and the age, sex or histology showed no significant effects (Supplementary Table S1 ). We further examined SCUBE3 expression in a lung adenocarcinoma invasion cell line model (CL 1À0 to CL 1À5 with increasing invasive ability) (Chu et al., 1997) and found that SCUBE3 mRNA and protein expression correlated with cell line invasiveness (Figure 1d ).
Knockdown of SCUBE3 expression suppresses cancer cell migration and invasion To validate whether SCUBE3 has a role in invasiveness, we engineered lentivirus-transduced stable knockdown of SCUBE3 in CL 1À5 cell lines by three individual shRNAs (shSCUBE3#1, shSCUBE3#2 and shSCUBE3#3) (Figure 2a, left) . We found that the knockdown of SCUBE3 expression was associated with inhibition of cancer cell migration and invasion (Figures 2b and c, left) . The SCUBE3 knockdown did not affect cancer cell growth, as shown by the cell proliferation and the anchorage-independent cell growth assays (Supplementary Figures S2 a and b) . In addition, the ability to adhere to the extracellular matrix proteins fibronectin, collagen IV, gelatin and laminin was not affected by SCUBE3 knockdown (Supplementary Figure S2c) .
To further validate the results, we also performed SCUBE3 knockdown in another highly invasive lung cancer cell line Hop62 (Figure 2a, right) . Like CL 1À5 cells, the SCUBE3 knockdown inhibited the cell mobility and invasiveness of the Hop62 cell lines (Figures 2b and c, right) .
Knockdown of SCUBE3 expression suppresses tumorigenesis and cancer metastasis in vivo To investigate the effect of SCUBE3 expression on tumorigenicity in vivo, a xenotransplantation assay in non-obese diabetic-severe combined immunodeficiency (SCID) mice was performed. SCUBE3 knockdown CL 1À5 cells or control cells were subcutaneously injected into the flanks of non-obese diabetic-SCID mice and the tumor volumes were measured twice a week. At 42 days after injection, the mice were killed. As shown in Figure 3a , tumor growth was gradually suppressed over the course of the experiment in non-obese diabetic-SCID mice injected with SCUBE3 knockdown CL 1À5 cells. In contrast, tumor growth ability was significantly developed in mice injected with control CL 1À5 cells. Taken together, these results demonstrate that the loss of SCUBE3 suppresses the tumorigenic ability of CL 1À5 cells in vivo.
On the basis of our in vitro data, we postulated that SCUBE3 expression would affect cancer cell metastasis. To determine the impact of SCUBE3 expression on metastatic colonization, we injected SCID mice intravenously with SCUBE3 knockdown CL 1À5 cells (CL 1À5 / shSCUBE3#2 and CL 1À5 /shSCUBE3#3) or control cells (CL 1À5 /shLacZ). At 6 weeks after injection, the mice were killed. As shown in Figure 3b , mice injected with SCUBE3 knockdown cells developed significantly fewer pulmonary metastatic nodules than those injected with control cells. These results indicate that SCUBE3 knockdown in CL 1-5 cells suppresses the ability of these cells to form metastatic nodules in the lungs.
SCUBE3 interacts with TbR-II through its C-terminal CUB domain
To explore the mechanism of SCUBE3's effect on invasive ability, we used the ProtoArray Human Protein Microarray (Invitrogen, Carlsbad, CA, USA) to examine the SCUBE3 interacting proteins. We found that the CUB domain of SCUBE3 interacted with the TbR-II (Figure 4a ). This result was confirmed by co-immunoprecipitation. Co-expression of TbR-II-hemagglutinin (HA) and Flag-SCUBE3 proteins in H1299 cells resulted in a specific co-precipitation of SCUBE3 and TbR-II, after immunoprecipitation by an anti-Flag antibody Figure S3 ). This analysis shows that SCUBE3 interacts with the extracellular region of TbR-II.
We further defined the TbR-II-binding domains of SCUBE3 by the glutathione-S-transferase (GST) pulldown assay, using the in vitro transcription and translation of HA-tagged TbR-II and different regions of GST-fused SCUBE3 proteins, SCUBE3-E1-9 (amino acids 23-399) containing EGF-like domain 1 to 9 and SCUBE3-S þ C (amino acids 400-993) containing the spacer region to the CUB domain (Figure 4c ). The estimated molecular sizes of the proteins were B70 and B100 kDa, respectively (Figure 4d, lower) . The western blot of the pull-down samples with an anti-HA antibody showed that the SCUBE3-S þ C protein interacted with TbR-II, whereas SCUBE3-E1-9 or control GST did not (Figure 4d, upper) . These data show that the SCUBE3 protein binds to TbR-II through its C-terminal CUB domain.
SCUBE3 induces TbR-II signaling
As SCUBE3 interacts with TbR-II, we wanted to explore whether SCUBE3 could activate TGF-b receptors and their signaling. We treated lung cancer cells with conditioned media containing the SCUBE3 protein. Conditioned media were obtained from the serumfree culture media in which H1299 cells transfected with SCUBE3-Myc-His expressing plasmid or control vector were incubated. We then treated recipient H1299 cells for 30 min with 25, 50 and 100% of the controlconditioned media or the SCUBE3-Myc-His-containing GST pull-down assays were performed using control GST, GST-E1-9 and GST-S þ C fusion proteins bound to Sepharose 4B by incubating with TbR-II-HA protein, an in vitro transcription/translation product. The pull-down samples were separated by SDS-PAGE and immunoblotted with anti-HA (upper). Lower: GST (26 kDa), GST-E1-9 (aa 23-399, B70 kDa) and GST-S þ C (aa 400-993, B100 kDa) fusion proteins were analyzed by SDS-PAGE and stained with Coomassie Blue.
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Y-Y Wu et al conditioned media, following a 6 h serum starvation. The SCUBE3-Myc-His-containing conditioned media induced Smad2 phosphorylation in a dose-dependent manner, whereas the vector control conditioned media did not (Figure 5a , left). Moreover, when SCUBE3 proteins were withdrawn from these conditioned media by immunoprecipitation with an anti-Myc antibody, the SCUBE3-withdrawn medium lost the inducing effect on Smad2 phosphorylation (Figure 5a, right) . From these results, we hypothesized that SCUBE3 was able to induce the TGF-b receptor signaling and its downstream Smad2/3 phosphorylation. To test this hypothesis, we purified SCUBE3 protein from the SCUBE3-Myc-His-containing conditioned media and then treated starved H1299 cells with different doses of purified SCUBE3-FL protein for 30 min, or treated with 5 nM purified SCUBE3 protein for 0, 5, 10, 20, 30, 45 and 60 min. Purified SCUBE3 protein induced Smad2/3 phosphorylation with a peak at 30-45 min (Supplementary Figures S4 a and b) .
SCUBE3 CUB domain is sufficient to bind TbR-II and induce Smad2/3 phosphorylation Secreted hSCUBE3 protein has recently been reported to be digested by a serum-associated protease, releasing the EGF-like repeats and the CUB domain (Wu et al., 2004 ). As we have previously shown that the CUB domain alone is sufficient to interact with TbR-II, we wanted to examine whether the CUB domain is sufficient to induce Smad2/3 phosphorylation. Recombinant SCUBE3-C-Myc-His protein containing the cysteine-rich and CUB domains was purified. Like SCUBE3-Myc-His protein, SCUBE3-C-Myc-His protein increased Smad2/3 phosphorylation with a peak at 30 min, supporting the idea that the C-terminus of SCUBE3 is sufficient to induce Smad2/3 phosphorylation (Supplementary Figures S4 c and d) . To ensure that SCUBE3-induced Smad2/3 phosphorylation is mediated through the activation of TGF-b receptors, we treated non-SCUBE3 expressing cells with the TbR-II decoy, sTbR-II (Supplementary Figures S5 a and b) , the neutralizing antibody to TbR-II (Supplementary Figure S5c) or an inhibitor of TGF-b type I receptor SB431542 (Figure 5b ), in the presence of SCUBE3-FL or SCUBE3-C protein. It appeared that SCUBE3-induced Smad2/3 phosphorylation was blocked by the TbR-II decoy and neutralizing antibody, as well as the TbR-I inhibitor in two different lung cancer cell lines, A549 (Figure 5b and Supplementary Figure S5 ) and H1299 cells (data not shown). To examine the participation of TGF-b, we treated A549 cells with a neutralizing antibody against TGF-b in the presence of SCUBE3-C protein (Supplementary Figure S6a) . SCUBE3-induced Smad2/3 phosphorylation was not affected by the TGF-b neutralizing antibody.
Next, we examined the CUB domain-induced Smad2/3 transcriptional activity by a reporter assay. We treated H1299 cells transfected with the TGF-b-responsive 3TP-lux reporter, with purified SCUBE3-C-Myc-His protein, TGF-b1 or both for 24 h. Treatment with TGF-b1 or SCUBE3-C-Myc-His protein increased the basal level of 3TP-lux reporter transcription in a dose-dependent manner. Co-treatment with TGF-b1 and SCUBE3-CMyc-His protein significantly enhanced the luciferase activity compared with TGF-b1 or SCUBE3-C-Myc-His protein alone (Figure 5c ). Moreover, to examine whether SCUBE3 affects the binding between TGF-b1 and TbR-II, we performed binding experiments of TGF-b1 to TbR-II in the presence or absence of SCUBE3 (Supplementary Figure S6b) . The results demonstrated that SCUBE3 did not compete for the binding between TGF-b1 and TbR-II. We then examined the expression of a number of Smad2/3 downstream genes by reverse transcriptase PCR, following SCUBE3 treatments in H1299 and A549 cells. Both SCUBE3 and SCUBE3-C treatment increased the expression of most of the Smad2/3 target genes in H1299 and A549 cells, including Slug, MMP-2, plasminogen activator inhibitor type-1 (PAI-1), TGF-b1 and vascular endothelial growth factor (VEGF) however, Snail and MMP-9 were only detectable in H1299 cells (Figure 5d and Supplementary Figure  S7 ). On the basis of the above results, SCUBE3, through its CUB domain, can bind and activate TGF-b receptors and trigger Smad2/3 phosphorylation and transcriptional activity.
SCUBE3 is cleaved by matrix metalloprotease-2 (MMP-2) and MMP-9 Recombinant Flag-SCUBE3 or SCUBE3-Myc protein, produced by H1299 cells, was prepared and used as a substrate for an in vitro cleavage reaction with purified recombinant MMP proteases, MMP-2 and MMP-9. The results show that SCUBE3 protein is cleaved by MMP-2 entirely, but is cleaved by MMP-9 to a lesser extent. The cleavage further resulted in the release of the N-terminal fragments, mainly containing the nine EGFlike repeats and a C-terminal 55-kDa fragment consisting of the cysteine-rich and CUB domain similar to the recombinant SCUBE3-C protein ( Figure 6 ).
SCUBE3 can trigger epithelial-mesenchymal transition (EMT)
TGF-b receptor signaling is known to trigger EMT and modulate the migration and invasion of cancer cells (Leivonen and Kahari, 2007) . Here we analyzed the expression of a number of EMT marker genes in SCUBE3-or SCUBE3-C-treated A549 lung cancer cells. Following treatment, the expression of the mesenchymal markers vimentin and slug were upregulated. Conversely, the expression of the epithelial marker E-cadherin was downregulated (Figure 7a) . Moreover, in a wound healing migration assay, SCUBE3-C protein significantly promoted the migration (Figure 7b ) of A549 cells and H1299 cells (data not shown).
Discussion
Our results indicate that SCUBE3 is overexpressed in lung cancer cells and may serve as an endogenous TbR-II ligand that may regulate EMT and cancer metastasis. The secreted SCUBE3 is cleaved by MMP-2 and ) were transfected with the control vector or the expression vector encoding human SCUBE3-Myc-His. After transfection, the cells were cultured with 3 ml serum-free Dulbecco's modified Eagle's medium. After 30 h, the conditioned culture media (vector control and SCUBE3-Myc-His) were collected. Then, 6 h-starved H1299 cells (8 Â 10 5 ) were treated with the indicated amounts of conditioned media for 30 min. Right: SCUBE3-Myc-His was withdrawn from the conditioned media, vector control (V) and SCUBE3-Myc-His (S3) by immunoprecipitation with an anti-Myc antibody. Cells were then treated with 1 ml conditioned or SCUBE3-withdrawn media. Cell lysates were analyzed by western blotting with the indicated antibodies. (b) SCUBE3-induced Smad2/ 3 phosphorylation is blocked by SB431542. H1299 cells starved for 6 h and pretreated with or without 2 mM SB431542 were treated for 30 min in the serum-free Dulbecco's modified Eagle's medium with 5 nM SCUBE3-FL-Myc-His or 3 nM SCUBE3-C-Myc-His. 
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MMP-9 to release the N-terminal EGF-like repeats fragment and the C-terminal CUB domain. Both SCUBE3 and the CUB domain fragments, either by themselves or along with TGF-b1, bind to TbR-II and activate TGF-b signaling, leading to the induction of Smad2/3 phosphorylation and the expression of downstream genes (that is, TGF-b1, MMP-2, MMP-9, PAI-1, VEGF, Snail and Slug). These genes are involved in the EMT process, thus promoting cancer invasion/metastasis, extracellular matrix deposition and angiogenesis (Figure 7c) . In this study, we showed that SCUBE3 and its C-terminal fragment could interact with TbR-II, subsequently activate TbR-I, and then induce Smad2/3-mediated transcriptional activation to regulate EMT. TGF-b signaling can act in either suppressing tumors or promoting tumors, depending on the course of cancer progression (Massague, 2008) . In early tumor stages, TGF-b signaling suppresses tumor growth through inducing cell cycle arrest and apoptosis. But during the later stage of tumorigenesis, it promotes cancer invasion and metastasis through epithelial to mesenchymal transdifferentiation. Accordingly, we observed that SCUBE3 knockdown repressed the invasive ability of highly invasive CL 1À5 or Hop62 lung cancer cells (Figure 2 ), but did not affect cell proliferation (Supplementary Figure S2, a and b) . In addition, SCUBE3 knockdown suppressed in vivo tumorigenesis and metastasis of CL 1À5 cells (Figure 3) . Furthermore, SCUBE3 and its C-terminal fragment induced EMT in the non-SCUBE3 expressing A549 cells (Figure 7 ). These data indicate that SCUBE3 may switch on the tumor-promoting functions of TGF-b receptor signaling. TGF-b signaling is regarded as the major inducer of EMT in vivo through the canonical Smad signaling or non-Smad pathways, such as mitogen-activated protein kinase signaling (that is, ERK, JNK and p38) and RhoA GTPase (Zhang, 2009) . However, in our investigation of the noncanonical pathways, we did not see a predominant increase in the phosphorylation levels of ERK, JNK or p38 in A549 or EKVX cells, following treatment with SCUBE3 protein or its C-terminal fragment (SCUBE3-C) compared with untreated cells (data not shown). According to these results, we have demonstrated that SCUBE3 induces EMT and promotes cancer mobility through its CUB domain, mainly through the canonical TGF-b receptors-Smad2/3 pathways at a late stage of lung cancer progression. Wu et al. (2004) have shown that secreted SCUBE3 protein can be cleaved in the presence of fetal bovine serum. We also found that SCUBE3 was digested in vitro by gelatinases (MMP-2 and MMP-9) to release a fragment similar to SCUBE3-C. To date, the exact proteases for SCUBE3 cleavage in vivo remain undiscovered.
Our data reveal that SCUBE3 induces the expression of TGF-b receptor-mediated genes involved in cancer progression, such as Snail, Slug, PAI-1, MMP-2, MMP-9 and VEGF in an autocrine or paracrine manner. Snail and Slug are known EMT inducers responsible for E-cadherin transcriptional silencing (Nieto, 2002; Peinado et al., 2007) , and are implicated in the invasiveness of many cancers (Elloul et al., 2005; Gupta et al., 2005; Martin et al., 2005; Roy et al., 2005; Shioiri et al., 2006) . We have previously reported that Slug promotes tumor invasion and acts as an independent prognostic marker in lung adenocarcinoma (Shih et al., 2005) . Another TGF-b upregulated gene, PAI-1 (SERPINE1), which is involved in the extracellular matrix remodeling, cell migration and tumor angiogenesis (Stefansson et al., 2003; Providence and Higgins, 2004; Binder and Mihaly, 2008) , is also an independent predictor of cancer relapse and poor survival in patients with breast, lung, ovarian and oral squamous cell carcinoma (Kuhn et al., 1999; Foekens et al., 2000; Hundsdorfer et al., 2004; Lader et al., 2004; Werle et al., 2004) . MMP-2 and MMP-9 have also been reported to promote tumor invasion and metastasis and act as prognostic factors in non-small cell lung cancer Figure 6 SCUBE3 is cleaved by purified recombinant MMP-2 and MMP-9 in vitro. (a) Flag-SCUBE3 proteins were immunoprecipitated with an anti-Flag antibody from cell lysates of H1299 cells transfected with an expression plasmid producing the Flag-SCUBE3 protein and were incubated with purified recombinant human MMP-2 or MMP-9 (500 ng) at 371C for 2 h in the absence or presence of a broad-spectrum MMP inhibitor (GM6001, 20 mM). Flag-SCUBE3 and its cleaved products were analyzed by SDS-PAGE and western blot analysis using an anti-Flag antibody.
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(b) In vitro cleavage of SCUBE3-Myc proteins by purified recombinant MMP-2 and MMP-9 was performed as in panel A. SCUBE3-Myc and its cleaved products were analyzed by SDS-PAGE and western blot analysis using an anti-Myc antibody.
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disrupting the extracellular matrix to allow for cell migration, MMPs also contribute to the release of bioactive molecules engaged in malignant transformation and cancer progression (Folgueras et al., 2004) . For example, MMP-2 and MMP-9 can release TGF-b from a latent TGF-b complex (Yu and Stamenkovic, 2000) and VEGF from the extracellular matrix or inhibitory complexes (Dean et al., 2007; Hollborn et al., 2007; Hawinkels et al., 2008) and are assumed to modulate angiogenesis. Moreover, VEGF, the most important factor of angiogenesis, is also upregulated by the SCUBE3-TGF-b receptor-signaling pathway. In addition to its role in tumor angiogenesis, our previous study has shown that VEGF promotes migration and invasion of tumor cells by directly acting on VEGFR2 and NRP1 (Hong et al., 2007) . Furthermore, SCUBE3 could also upregulate TGF-b1 expression and function with TGFb1, resulting in further activation of the TGF-b receptor signaling pathway. According to the result shown in Supplementary Figure S6a , SCUBE3 induced Smad2 phosphorylation in the absence of TGF-b. In addition, SCUBE3 also cooperated with TGF-b1 in signaling to promote the transcriptional activity of Smad2/3 ( Figure 5c ) and did not compete for the binding of TGF-b1 with TbR-II (Supplementary Figure S6b) . These data support the notion that SCUBE3 activates the TGF-b receptor by itself or along with TGF-b1, although the nature of the binding of TbR-II to SCUBE3 and TGF-b1 is still not clear. Cancer cells can secrete factors to create a tumor microenvironment to support their progression. SCUBE3 secreted by cancer cells may induce additional tumor promoting factors, such as TGF-b1, MMP-2 and MMP-9, in an autocrine and paracrine manner to enhance the function of SCUBE3 or TGF-b receptor signaling, which further facilitates cancer progression. 
In conclusion, our data strongly suggest that SCUBE3 is a TbR-II ligand in the tumor microenvironment. SCUBE3 may have a critical role, together with TGF-b, in controlling EMT, angiogenesis and cancer metastasis through the TGF-b receptors-Smad2/3 pathway. The present observations raise the possibility that SCUBE3 might provide new opportunities for therapeutic intervention.
Materials and methods
Patient and tumor specimens
Lung tumor tissue and adjacent normal tissue specimens used in the reverse transcriptase PCR analysis were obtained from 18 patients with histologically confirmed non-small cell lung cancer who underwent surgical resection at the National Taiwan University Hospital (Taipei, Taiwan, ROC). The specimens from 60 patients used for immunohistochemical staining were obtained from the same source between 2000 and 2003. None of the patients had received preoperative adjuvant chemotherapy or radiation therapy. This investigation was approved by the Institutional Review Board of the National Taiwan University Hospital. Written informed consent was obtained from all patients.
Cell lines
A panel of human lung adenocarcinoma cell lines, CL 1À0 , CL 1À1 and CL 1À5 , in ascending order of invasiveness, was established in our laboratory. H1299 and A549 cells were purchased from the ATCC (Manassas, VA, USA). EKVX and Hop62 cells were kind gifts from Dr, Ker-Chau Li (Institute of Statistical Science, Academia Sinica, Taiwan).
Reverse-transcriptase PCR (RT-PCR)
Total RNA and cDNA was prepared and analyzed by PCR, as described previously (Wang et al., 2009) . The size and amount of the PCR products generated were determined by agarose gel electrophoresis in the presence of ethidium bromide. Gb-like was used for normalization. The quantity of SCUBE3 mRNA expression in patients was presented as the expression in tumors compared with their paired normal tissues. The characteristics of the primer sequences are listed in Supplementary Table S2 .
Immunoprecipitation and western blot analysis Samples were immunoprecipitated, and a western blot analysis was conducted as described (Wang et al., 2009 ). An endogenous SCUBE3 polyclonal antibody was produced, using a purified C-terminal region of SCUBE3 protein with a His tag. The specificity of the antibody was characterized with appropriate positive and negative controls with pre-immune serum. The anti-b-actin monoclonal antibody was purchased from Sigma (St Louis, MO, USA), anti-phospho-Smad2, Smad2, phospho-Smad3 and Smad3 were from Cell Signaling Technology (Beverly, MA, USA), anti-vimentin and anti-E-cadherin monoclonal antibodies were from BD sciences (San Jose, CA, USA), and the anti-Slug polyclonal antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Identification of SCUBE3 interacting proteins by protein microarray
The protein microarray experiment was performed with a ProtoArray Human Protein Microarray nc v1.0 (Invitrogen).
Approximately 1800 human proteins were expressed as a fusion protein with GST at the N-terminus, using a baculovirus expression system and then purified from insect cells and printed in duplicate on the array. Biotinylated GST and GST-CUB domain of SCUBE3 fusion proteins (aa 802-993) were used to interact with the protein microarray. In the array experiment, the microarray slide was blocked with blocking buffer (1 Â phosphate buffered saline, 1% bovine serum albumin and 0.1% Tween-20) for 1 h at 4 1C. Interaction was performed with 120 ml of 1 mM protein in the buffer (1 Â phosphate buffered saline, 5 mM MgCl 2 , 0.5 mM dithiothreitol, 0.05% Triton X-100, 5% Glycerol, 1% bovine serum albumin) for 90 min at 4 1C. After interaction, the microarray slide was washed twice with 20 ml probing buffer for 5 min. To detect the SCUBE3 interacting proteins on the slide, the array was incubated in the dark with 120 ml of AlexaFluor 647-labeled Neutravidin (Invitrogen) at 4 1C for 30 min. The slide was then washed three times with 20 ml probing buffer for 5 min. The microarray slide was scanned using the GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA) and the image was analyzed using GenePix Pro 4.0 software (Molecular Devices). Statistically significant SCUBE3 interacting proteins were identified by ProtoArray Prospector Software (Invitrogen).
SCUBE3 protein purification
Confluent H1299 cells, which stably expressed and secreted His-and Myc-tagged SCUBE3 full length or C-terminal protein, were maintained in media containing 0.5% fetal bovine serum. The conditioned media were collected every 2-3 days. The C-terminal His-tagged SCUBE3 was purified by affinity chromatography with nickel-nitrilotriacetic acid resin (Qiagen, Valencia, CA, USA), according to the manufacturer's protocol. The purified recombinant protein was dialyzed in phosphate buffered saline to remove the denaturant.
Wound healing assay Cells were seeded on 12-well culture plates. After the cells had formed a monolayer, a wound was created using a 200-ml pipette tip. Cell migration was observed, and the cells were photographed at 0, 10 or 12 h, following the creation of the wound. The number of cells that migrated into the cell-free zone was also evaluated.
In vitro invasion assay
The invasive activity of stable clones was examined using a membrane invasion culture system chamber, as previously described (Hong et al., 2007) . Each sample was assayed in triplicate.
In vivo tumorigenesis assay For tumor implantation, 5 Â 10 6 cells were subcutaneously injected into 8-week-old male non-obese diabetic-SCID mice. Tumor size was measured twice a week with calipers using the formula: V ¼ ab 2 /2, where a is the length and b is the width of the tumor (Hong et al., 2007) . All animal experiments were performed in accordance with the animal guidelines of the Department of Animal Care, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, ROC.
Experimental metastasis in vivo A single-cell suspension containing 5 Â 10 5 cells in 0.1 ml phosphate buffered saline was injected into the lateral tail veins of 7-week-old SCID mice. After 6 weeks, the animals were killed, and the lungs were removed and fixed in 10% formalin. The number of lung tumor colonies was counted under a dissecting microscope. Representative lung tumors were embedded in paraffin, sliced into 4-mm sections and stained with hematoxylin-eosin for histological analysis.
In vitro transcription and translation and GST pull-down assay In vitro transcription and translation of TbR-II protein was performed using the TNT transcription-translation system (Promega, San Luis Obispo, CA, USA). GST fusion proteins SCUBE3-E1-9 (aa 23-399) containing EGF-like domain 1 to 9 and SCUBE3-S þ C (aa 400-993) containing the spacer region to the CUB domain were prepared. Equal amounts of each of the different GST fusion proteins bound to glutathione-sepharose 4B beads were then incubated for 2 h at 4 1C, with the TbR-II-HA protein produced by in vitro transcription and translation. After the incubation, the fusion protein-sepharose 4B complexes were collected by centrifugation and washed five times with buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 8.0), 100 mM KCl, 0.2 mM EDTA, 0.5 mM dithiothreitol). The bound proteins were eluted by heating the beads at 95 1C for 5 min in 2 Â sodium dodecyl sulfate sample buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting.
Luciferase activity assays H1299 cells (3 Â 10 5 cells per well) were seeded into 6-well plates. Plasmids were transfected into the cells using Lipofectamine 2000 reagents (Invitrogen, Eugene, OR, USA). The luciferase reporter 3TP-Lux was co-transfected with a b-galactosidase construct, pSV-b-Gal (Promega), at a DNA ratio of 3:1. At 24-h post-transfection, the transfected cells were treated with TGF-b1 or purified SCUBE3-C-myc-his protein for 24 h. Luciferase activity and b-galactosidase activity were measured using a luciferase assay kit and Galacto-Light chemiluminescent assay kit (Tropix, Bedford, MA, USA). Transfection efficiency was normalized with bgalactosidase activity. Data are expressed as relative luciferase activity (firefly luciferase activity divided by b-galactosidase activity).
In vitro digestion of SCUBE3 by purified recombinant matrix metalloproteinases (MMPs) The Flag-or Myc-tagged SCUBE3 protein produced by H1299 cells was incubated with various recombinant MMPs (500 ng; R&D Systems, Minneapolis, MN, USA) in the absence or presence of a broad-spectrum MMP inhibitor (GM6001, 20 mM, Merck, Darmstadt, Germany), in buffer containing 20 mM Tris-HCl, (pH 7.4), 5 mM CaCl 2 , 150 mM NaCl, 0.05% Brij-35 at 37 1C for 2 h. The cleaved fragments were analyzed by probing with anti-Flag (N-terminus) or antiMyc (C-terminus) antibodies.
Statistical analysis
Data are presented as averages and their respective standard deviation (s.d.). All statistical analyses were performed with the SPSS Statistical Program (version 12.0; SPSS, Chicago, IL, USA). Comparisons of data between two groups were made with Student's t-test. Univariate analysis of patient characteristics was conducted by Fisher's exact test. All statistical tests were two-sided and P values of o0.05 were considered statistically significant.
The detailed methodology for all other analyses is described in Supporting information, Supplementary Materials.
